Remove Cannabis Remove DEA Remove Patients Remove Events
article thumbnail

Why Dr. Sue Sisley Sued the DEA for Stonewalling Cannabis Research

NORML

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials.

DEA 230
article thumbnail

U.S. Federal Court Tells DEA to Evaluate Rescheduling Cannabis, in Light of its Medical Benefits

WeedAdvisor

In a rather surprising turn of events, a federal appeals court gave marijuana advocates a small opening in their ongoing battle to reschedule marijuana, according to Marijuana Moment. The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA.

DEA 55
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Psychedelics Activists Protest Outside DEA’s Offices – Arrests Made

Cannabis Law Report

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. Patients, veterans and key advocates participated in the demonstration. aeidinger) May 9, 2022.

DEA 52
article thumbnail

5 Medical Cannabis Strains That Can be Used to Treat PTSD

FloridaMarijuana.net

5 cannabis strains to treat PTSD? The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. Medical marijuana can contribute to a patient’s overall health. 5 cannabis strains to treat PTSD: 1. Blue Dream.

Strains 190
article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.

DEA 52
article thumbnail

4 Reasons You Shouldn’t Miss CannMed 23 

Medicinal Genomics

The CannMed 23 Innovation and Investment Summit is a cannabis industry event like no other. Set at the beautiful Marriot Marco Island Resort, CannMed 23 provides an immersive forum where cannabis researchers, physicians, patients, entrepreneurs, and investors can collaborate and share their latest innovations and insights.

article thumbnail

Legal Acceptance of Cannabis Could Encourage Lawmakers to Embrace Magic Mushrooms

Veriheal

Cannabis’ former reputation as a gateway drug may have been dispelled, but it turns out that there is some element of truth to the rumor: The plant’s progressively evolving status as a normalized medicine in 37 U.S. There is also the possibility of losing control and having flashbacks from tragic events. What Is Psilocybin?